Our data show that FRβ+ TAMs can be selectively and efficiently depleted in vivo through the administration of FRβ-specific CAR-T cells, resulting in controlled tumor progression in three different preclinical tumor models and improved survival in the ID8 ovarian cancer model. Here, FOLR2 is linked to ovarian cancer.